bearish
Hansoh Pharma (翰森制药) Post-IPO Trading Update: Fairly Valued
560 Views17 Jun 2019 07:16
Hansoh Pharma's IPO was priced at the high end and started trading last Friday. In our earlier note, we argued that the company should trade at...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hansoh Pharma's Lock-Up Expiry: Valuation and the Trade05 Dec 2019
- Hansoh Pharma's Lock-Up Expiry - New Drugs Offset the Impact of Centralized Procurement04 Dec 2019
- Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports10 Oct 2019
- Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End30 May 2019
- Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal29 May 2019
x